Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of KJ103 in Guillain-Barré syndrome
CTR20253992Phase 2Active
- Sponsor
- Shanghai Baoji Pharmaceutical
- Start
- Nov 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ricefidase in Guillain-Barré syndrome (GBS), sponsored by Shanghai Baoji Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
ricefidase
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on CTR20253992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253992.